It was through MHIN that Broderick developed a close rapport with Prolog's other partners -- Ilya Nykin and Brian Clevinger. After Broderick's fund invested in ZyStor Therapeutics, one of the most promising ventures in Prolog's portfolio, he joined Clevinger on the company's board of directors. The two also have served together at several industry organizations including BioGenerator, InvestMidwest, and BIO Mid-America Venture Forum.
"I was attracted to Prolog because it has one of the most innovative and effective investment teams in the venture capital business," said Broderick. "I especially admire this firm for being committed since inception to balancing traditional healthcare investing with focused and resourceful pursuit of opportunities in emerging areas of life science. I am convinced this investment approach is the wave of the future and am excited to help the firm build on its early leadership position."
Prolog is a venture capital firm specializing in life science
investing. Since its launch in 2001, Prolog has financed more than 20
early-stage companies. The firm is managed by a team of professionals with
extensive experience as both investors and entrepreneurs. Prolog focuses on
traditional healthcare opportunities as well as emerging areas - such as
nutrition, wellness, plant science, and enabling platforms - in which it
has built one of the largest portfolios in the country. For more
information, visit http://www.prolo
|SOURCE Prolog Ventures|
Copyright©2007 PR Newswire.
All rights reserved